Rytary

My Neurologist told me about a new form of L-Dopa that's about to be released called Rytary. As you're most likely aware, Rytary is an extended release oral L-DOPA formulation that is comprised of small beads.The beads release L-DOPA slowly as it goes through the small intestine.

Oct 12, 2012- Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Rytary (IPX066) New Drug Application (NDA) from October 21, 2012, to January 21, 2013.

About Rytary

Rytary is an investigational extended release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease. It is not approved or licensed anywhere in the world. Results from the pivotal phase III studies of IPX066, APEX-PD (early PD), ADVANCE-PD (advanced PD) and ASCEND-PD (advanced PD) have previously been announced